28 related articles for article (PubMed ID: 8420138)
1. Transcriptome-based biomarker prediction for Parkinson's disease using genome-scale metabolic modeling.
Abdik E; Çakır T
Sci Rep; 2024 Jan; 14(1):585. PubMed ID: 38182712
[TBL] [Abstract][Full Text] [Related]
2. Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.
Palomo T; Beninger RJ; Kostrzewa RM; Archer T
Neurotox Res; 2003; 5(1-2):1-26. PubMed ID: 12832221
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of the new COMT inhibitor CGP 28,014.
Bieck PR; Antonin KH; Farger G; Nilsson EB; Schmidt EK; Dostert P; Strolin Benedetti M; Waldmeier PC
Neurochem Res; 1993 Nov; 18(11):1163-7. PubMed ID: 8255368
[TBL] [Abstract][Full Text] [Related]
4. Salsolinol and norsalsolinol in human urine samples.
Musshoff F; Daldrup T; Bonte W; Leitner A; Lesch OM
Pharmacol Biochem Behav; 1997 Oct; 58(2):545-50. PubMed ID: 9300617
[TBL] [Abstract][Full Text] [Related]
5. Increased systemic levels of norsalsolinol derivatives are induced by levodopa treatment and do not represent biological markers of Parkinson's disease.
Scholz J; Klingemann I; Moser A
J Neurol Neurosurg Psychiatry; 2004 Apr; 75(4):634-6. PubMed ID: 15026514
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous gas chromatographic-mass spectrometric determination of dopamine, norsalsolinol and salsolinol enantiomers in brain samples of a large human collective.
Musshoff F; Lachenmeier DW; Kroener L; Schmidt P; Dettmeyer R; Madea B
Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):837-49. PubMed ID: 14528920
[TBL] [Abstract][Full Text] [Related]
7. [Salsolinol, an endogenous molecule. Possible implications in alcoholism, Parkinson's disease and pain].
Vernay D; Eschalier A; Durif F; Aumaitre O; Rigal B; Ben Sadoun A; Fialip J; Marty H; Philip E; Bougerolle AM
Encephale; 1989; 15(6):511-6. PubMed ID: 2515055
[TBL] [Abstract][Full Text] [Related]
8. Dopamine-related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption.
Collins MA; Nijm WP; Borge GF; Teas G; Goldfarb C
Science; 1979 Dec; 206(4423):1184-6. PubMed ID: 505002
[TBL] [Abstract][Full Text] [Related]
9. Dopamine-derived tetrahydroisoquinolines and Parkinson's disease.
Dostert P; Strolin Benedetti M; Della Vedova F; Allievi C; La Croix R; Dordain G; Vernay D; Durif F
Adv Neurol; 1993; 60():218-23. PubMed ID: 8420138
[TBL] [Abstract][Full Text] [Related]
10. N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease.
Naoi M; Maruyama W
Adv Neurol; 1999; 80():259-64. PubMed ID: 10410730
[No Abstract] [Full Text] [Related]
11. N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease.
Naoi M; Maruyama W; Dostert P; Hashizume Y
J Neural Transm Suppl; 1997; 50():89-105. PubMed ID: 9120428
[TBL] [Abstract][Full Text] [Related]
12. Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains.
Naoi M; Maruyama W; Nagy GM
Neurotoxicology; 2004 Jan; 25(1-2):193-204. PubMed ID: 14697894
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
